Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PKX-001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : ProtoKinetix
Deal Size : Undisclosed
Deal Type : Partnership
Details : The ProtoKinetix-IQVIA collaboration will aim to accelerate the clinical development and regulatory progress of PKX-001. The collaboration is expected to drive directed clinical development as PKX-001 enters Phase 1 testing for the above conditions.
Product Name : PKX-001
Product Type : Peptide
Upfront Cash : Undisclosed
December 05, 2021
Lead Product(s) : PKX-001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : ProtoKinetix
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of telehealth technologies, virtual oversight, and digital patient engagement strategies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
August 03, 2021
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
Details : IQVIA Biotech is positioned to collaborate with ASLAN on development plans for ASLAN003 in inflammatory bowel disease, with clinical trials commencing early next year. Enrollment of the first patient in the ASLAN004 Phase 2b trial is expected in the four...
Product Name : ASLAN004
Product Type : Antibody
Upfront Cash : Undisclosed
June 12, 2021
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Dexmethylphenidate,Serdexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.
Product Name : Azstarys
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Dexmethylphenidate,Serdexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Walter And Eliza Hall Institute Of Medical Research
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The COVID SHIELD clinical study will test an expanded indication for generic Hydroxychloroquine (HCQ) as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 20, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Walter And Eliza Hall Institute Of Medical Research
Deal Size : Undisclosed
Deal Type : Collaboration